MINDMAZE THERAPEUTICS HOLDING SA

MINDMAZE THERAPEUTICS HOLDING SA

MMTX · SW · Healthcare / Biotechnology

0.1386CHF-0.00 (-0.72%)

Price History

Full chart

Market Stats

Previous Close0.1396
Open0.1398
Day Range0.138 – 0.147
52-Week Range0.1356 – 2.99
Volume1.03M
Market Cap23.56M
P/E (TTM)0.00
Forward P/E1.02
EPS-0.24
Dividend Yield0.00%
50-Day Avg0.1831
200-Day Avg0.5656

About

MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics' neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson's therapy-reimagined through play. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Zachery W. Henderson
  • Employees10
  • HeadquartersAvenue de Sécheron 15, Geneva, Switzerland, 1202, Switzerland
  • Websitehttps://mindmazetherapeutics.com

Leadership

  • Mr. Zachery W. HendersonCEO & Director · b. 1973
  • Mr. Jeremy Meinen CPAChief Financial Officer · b. 1989
  • Mr. Alexandre CapetChief Operating & Strategy Officer · b. 1973
  • Mr. Frédéric CondoloChief Technology Officer · b. 1973

Financials

Income Statement

Currency: CHF2024-12-312025-12-31
Total Revenue0642.00K
Cost of Revenue051.00K
Gross Profit0591.00K
Gross Margin-92.06%
Operating Expense2.00K11.11M
Operating Income-2.00K-10.52M
Operating Margin--1637.85%
EBITDA-1.00K-8.00M
EBITDA Margin--1246.26%
Net Income-1.00K-9.91M
Net Income Margin--1542.99%
R&D05.29M
R&D as % of Total Revenue-823.83%
Interest Expense0266.00K
Interest Expense % of Total Revenue-41.43%

Balance Sheet

Currency: CHF2024-12-312025-12-31
Total Assets93.00K51.53M
Total Liabilities7.00K13.19M
Total Equity86.00K38.34M
Cash09.47M

Cash Flow

Currency: CHF2024-12-312025-12-31
Operating Cash Flow-3.00K-7.21M
Capital Expenditure022.00K
Free Cash Flow-3.00K-7.23M
FCF to OCF100.00%100.31%

Earnings

Report DateSep 30, 2009Dec 31, 2009Dec 31, 2013Feb 3, 2016Aug 4, 2016Jun 1, 2017Sep 21, 2017Apr 30, 2018Jan 8, 2019May 6, 2019Nov 27, 2019Apr 30, 2020Sep 15, 2020Apr 15, 2021Sep 24, 2021Mar 31, 2022Sep 15, 2022Apr 14, 2023Apr 30, 2024Apr 10, 2025Aug 14, 2025
EPS Estimate---0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
EPS Actual-20.81-28.70-0.010.000.00-0.010.000.000.000.000.000.000.00-0.010.00-0.01-0.01-0.01-3.36-0.50-0.36
Surprise---------------------
Timing---------------------

Key Statistics & Ratios

Market Cap23.56M
Enterprise Value18.98M
Trailing P/E0.00
Forward P/E1.02
Price / Sales19.70
Price / Book0.68
EPS-0.24
Book Value0.211
Revenue (TTM)1.20M
Gross Profit (TTM)1.08M
EBITDA-10.21M
Profit Margin0.00%
Operating Margin-1144.71%
Return on Equity-51.56%
Return on Assets-25.46%
Shares Outstanding169.99M
Shares Float51.11M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%